Multiple Myeloma (Kahler Disease) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Multiple Myeloma (Kahler Disease) – Pipeline Review, H1 2017’, provides an overview of the Multiple Myeloma (Kahler Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease)

The report reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Multiple Myeloma (Kahler Disease) therapeutics and enlists all their major and minor projects

The report assesses Multiple Myeloma (Kahler Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Multiple Myeloma (Kahler Disease)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

AB Science SA

AbbVie Inc

Acceleron Pharma Inc

Actinium Pharmaceuticals Inc

Active Biotech AB

Adaptimmune Therapeutics Plc

Aduro BioTech Inc

Aeglea BioTherapeutics Inc

Affimed GmbH

AIMM Therapeutics BV

Alissa Pharma

Altor BioScience Corp

Amgen Inc

Anthera Pharmaceuticals Inc

APIM Therapeutics AS

Arno Therapeutics Inc

Array BioPharma Inc

Arvinas Inc

Asana BioSciences LLC

Aslan Pharmaceuticals Pte Ltd

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Aurigene Discovery Technologies Ltd

Bayer AG

Bellicum Pharmaceuticals Inc

BeyondSpring Pharmaceuticals Inc

Biotest AG

bluebird bio Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Calithera Biosciences Inc

CanBas Co Ltd

Celgene Corp

Cell Source Inc

Cellectar Biosciences Inc

Cellectis SA

Cellerant Therapeutics Inc

Celleron Therapeutics Ltd

CellProtect Nordic Pharmaceuticals AB

Celyad SA

Chong Kun Dang Pharmaceutical Corp

Chugai Pharmaceutical Co Ltd

Cleave Biosciences Inc

Curis Inc

Cyclacel Pharmaceuticals Inc

Daiichi Sankyo Company Ltd

DC Prime BV

Eli Lilly and Company

Enceladus Pharmaceuticals BV

eTheRNA Immunotherapies NV

Exelixis Inc

F. Hoffmann-La Roche Ltd

Five Prime Therapeutics Inc

Galileo Research srl

Gamida Cell Ltd

Genenta Science srl

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Gliknik Inc

GlycoMimetics Inc

GP Pharm SA

Heidelberg Pharma GmbH

HitGen LTD

IGF Oncology LLC

ImmunGene Inc

Immunomedics Inc

Incyte Corp

Inflection Biosciences Ltd

Inventiva

Jasco Pharmaceuticals LLC

Johnson & Johnson

Juno Therapeutics Inc

JW Pharmaceutical Corp

Kancera AB

Karus Therapeutics Ltd

Karyopharm Therapeutics Inc

Kesios Therapeutics Ltd

Kite Pharma Inc

Klyss Biotech Inc

Leadiant Biosciences Inc

MediGene AG

MedImmune LLC

Merck & Co Inc

Millennium Pharmaceuticals Inc

MimiVax LLC

Molecular Partners AG

Molecular Templates Inc

MolMed SpA

MorphoSys AG

NantKwest Inc

NBE-Therapeutics AG

Neonc Technologies Inc

Nippon Kayaku Co Ltd

Nordic Nanovector ASA

Novartis AG

Noxxon Pharma AG

Oncodesign SA

Oncolytics Biotech Inc

Onconova Therapeutics Inc

Oncopeptides AB

OncoTartis Inc

Ono Pharmaceutical Co Ltd

OXIS International Inc

Peptinov SAS

Pfizer Inc

Pharma Mar SA

Polyphor Ltd

Prescient Therapeutics Ltd

Progenra Inc

Quimatryx SL

RedHill Biopharma Ltd

Rhizen Pharmaceuticals SA

Sanofi

Seattle Genetics Inc

Selvita SA

Senhwa Biosciences Inc

Shuttle Pharmaceuticals LLC

Sorrento Therapeutics Inc

Spectrum Pharmaceuticals Inc

Stemline Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

Surface Oncology Inc

Sutro Biopharma Inc

Taiho Pharmaceutical Co Ltd

Takeda Pharmaceutical Company Ltd

TeneoBio Inc

Terpenoid Therapeutics Inc

Teva Pharmaceutical Industries Ltd

Tiziana Life Sciences Plc

TRACON Pharmaceuticals Inc

Transgene Biotek Ltd

Trillium Therapeutics Inc

Vaccibody AS

Vaxil Bio Therapeutics Ltd

Visterra Inc

Vivolux AB

XTL Biopharmaceuticals Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 9

Multiple Myeloma (Kahler Disease) - Overview 10

Multiple Myeloma (Kahler Disease) - Therapeutics Development 11

Multiple Myeloma (Kahler Disease) - Therapeutics Assessment 53

Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development 78

Multiple Myeloma (Kahler Disease) - Drug Profiles 154

Multiple Myeloma (Kahler Disease) - Dormant Projects 1133

Multiple Myeloma (Kahler Disease) - Discontinued Products 1147

Multiple Myeloma (Kahler Disease) - Product Development Milestones 1150

Appendix 1163

List of Tables

List of Tables

Number of Products under Development for Multiple Myeloma (Kahler Disease), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Products under Development by Companies, H1 2017 (Contd..14), H1 2017

Products under Development by Companies, H1 2017 (Contd..15), H1 2017

Products under Development by Companies, H1 2017 (Contd..16), H1 2017

Products under Development by Companies, H1 2017 (Contd..17), H1 2017

Products under Development by Companies, H1 2017 (Contd..18), H1 2017

Products under Development by Companies, H1 2017 (Contd..19), H1 2017

Products under Development by Companies, H1 2017 (Contd..20), H1 2017

Products under Development by Companies, H1 2017 (Contd..21), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..9), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by 4SC AG, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by AB Science SA, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by AbbVie Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Acceleron Pharma Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Actinium Pharmaceuticals Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Active Biotech AB, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Adaptimmune Therapeutics Plc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Aduro BioTech Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Aeglea BioTherapeutics Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Affimed GmbH, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by AIMM Therapeutics BV, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Alissa Pharma, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Altor BioScience Corp, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Amgen Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Anthera Pharmaceuticals Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by APIM Therapeutics AS, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Arno Therapeutics Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Array BioPharma Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Arvinas Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Asana BioSciences LLC, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Astellas Pharma Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Astex Pharmaceuticals Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by AstraZeneca Plc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Atara Biotherapeutics Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Aurigene Discovery Technologies Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Bayer AG, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Bellicum Pharmaceuticals Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Biotest AG, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by bluebird bio Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Boston Biomedical Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Bristol-Myers Squibb Company, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Calithera Biosciences Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by CanBas Co Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Celgene Corp, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Cell Source Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Cellectar Biosciences Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Cellectis SA, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Cellerant Therapeutics Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Celleron Therapeutics Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by CellProtect Nordic Pharmaceuticals AB, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Celyad SA, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Cleave Biosciences Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Curis Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by DC Prime BV, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Eli Lilly and Company, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Enceladus Pharmaceuticals BV, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by eTheRNA Immunotherapies NV, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Exelixis Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Five Prime Therapeutics Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Galileo Research srl, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Gamida Cell Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Genenta Science srl, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by GlaxoSmithKline Plc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Gliknik Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by GlycoMimetics Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by GP Pharm SA, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Heidelberg Pharma GmbH, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by HitGen LTD, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by IGF Oncology LLC, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by ImmunGene Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Immunomedics Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Incyte Corp, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Inflection Biosciences Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Inventiva, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Jasco Pharmaceuticals LLC, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Johnson & Johnson, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Juno Therapeutics Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by JW Pharmaceutical Corp, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Kancera AB, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Karus Therapeutics Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Karyopharm Therapeutics Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Kesios Therapeutics Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Kite Pharma Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Klyss Biotech Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Leadiant Biosciences Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by MediGene AG, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by MedImmune LLC, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Merck & Co Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Millennium Pharmaceuticals Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by MimiVax LLC, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Molecular Partners AG, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Molecular Templates Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by MolMed SpA, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by MorphoSys AG, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by NantKwest Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by NBE-Therapeutics AG, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Neonc Technologies Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Nippon Kayaku Co Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Nordic Nanovector ASA, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Novartis AG, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Noxxon Pharma AG, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Oncodesign SA, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Oncolytics Biotech Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Onconova Therapeutics Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Oncopeptides AB, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by OncoTartis Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by OXIS International Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Peptinov SAS, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Pfizer Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Pharma Mar SA, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Polyphor Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Prescient Therapeutics Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Progenra Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Quimatryx SL, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by RedHill Biopharma Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Rhizen Pharmaceuticals SA, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Sanofi, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Seattle Genetics Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Selvita SA, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Senhwa Biosciences Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Shuttle Pharmaceuticals LLC, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Sorrento Therapeutics Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Spectrum Pharmaceuticals Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Stemline Therapeutics Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Surface Oncology Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Sutro Biopharma Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by TeneoBio Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Terpenoid Therapeutics Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Tiziana Life Sciences Plc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by TRACON Pharmaceuticals Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Transgene Biotek Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Trillium Therapeutics Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Vaccibody AS, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Vaxil Bio Therapeutics Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Visterra Inc, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by Vivolux AB, H1 2017

Multiple Myeloma (Kahler Disease) – Pipeline by XTL Biopharmaceuticals Ltd, H1 2017

Multiple Myeloma (Kahler Disease) – Dormant Projects, H1 2017

Multiple Myeloma (Kahler Disease) – Dormant Projects, H1 2017 (Contd..1), H1 2017

Multiple Myeloma (Kahler Disease) – Dormant Projects, H1 2017 (Contd..2), H1 2017

Multiple Myeloma (Kahler Disease) – Dormant Projects, H1 2017 (Contd..3), H1 2017

Multiple Myeloma (Kahler Disease) – Dormant Projects, H1 2017 (Contd..4), H1 2017

Multiple Myeloma (Kahler Disease) – Dormant Projects, H1 2017 (Contd..5), H1 2017

Multiple Myeloma (Kahler Disease) – Dormant Projects, H1 2017 (Contd..6), H1 2017

Multiple Myeloma (Kahler Disease) – Dormant Projects, H1 2017 (Contd..7), H1 2017

Multiple Myeloma (Kahler Disease) – Dormant Projects, H1 2017 (Contd..8), H1 2017

Multiple Myeloma (Kahler Disease) – Dormant Projects, H1 2017 (Contd..9), H1 2017

Multiple Myeloma (Kahler Disease) – Dormant Projects, H1 2017 (Contd..10), H1 2017

Multiple Myeloma (Kahler Disease) – Dormant Projects, H1 2017 (Contd..11), H1 2017

Multiple Myeloma (Kahler Disease) – Dormant Projects, H1 2017 (Contd..12), H1 2017

Multiple Myeloma (Kahler Disease) – Dormant Projects, H1 2017 (Contd..13), H1 2017

Multiple Myeloma (Kahler Disease) – Discontinued Products, H1 2017

Multiple Myeloma (Kahler Disease) – Discontinued Products, H1 2017 (Contd..1), H1 2017

Multiple Myeloma (Kahler Disease) – Discontinued Products, H1 2017 (Contd..2), H1 2017

List of Figures

List of Figures

Number of Products under Development for Multiple Myeloma (Kahler Disease), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports